Perspectives of primary care clinicians on teratogenic risk counseling
- PMID: 19591115
- PMCID: PMC2805273
- DOI: 10.1002/bdra.20599
Perspectives of primary care clinicians on teratogenic risk counseling
Abstract
Background: Women of childbearing age are commonly prescribed medications by primary care providers (PCPs) that may cause birth defects if used during pregnancy.
Methods: To identify what PCPs perceive as barriers to and potential facilitators of providing counseling to women of childbearing age when teratogenic medications are prescribed, we conducted eight focus groups with 48 PCPs recruited from four clinical settings in Pittsburgh, Pennsylvania. We explored PCPs' experiences counseling women about teratogenic medications. Each focus group was audio-recorded, transcribed, and coded using a grounded theory approach by three independent coders.
Results: PCPs feel responsible for counseling women when they prescribe medications that may cause birth defects, but note difficulties identifying clinically relevant sources of information on teratogenicity. Other barriers to providing counseling include limited visit times and lack of reimbursement for preconception or teratogenic risk counseling. PCPs find it challenging to identify patients who may become pregnant and who therefore need contraceptive and/or teratogenic risk counseling. PCPs expressed a desire for online resources that could be used when explaining medication risks to patients. PCPs feel that the development of patient information materials, electronic decision support tools, clinical care systems that routinely assess patients' pregnancy risk, and changes in the reimbursement structure may facilitate counseling patients about teratogenic risks.
Conclusions: PCPs perceive themselves as playing an important role in providing their patients information on risk of medication-induced birth defects. To ensure safe prescription of teratogenic medications, PCPs suggest interventions at both the clinic and healthcare system levels.
Conflict of interest statement
Similar articles
-
Women's perspectives on counseling about risks for medication-induced birth defects.Birth Defects Res A Clin Mol Teratol. 2010 Jan;88(1):64-9. doi: 10.1002/bdra.20618. Birth Defects Res A Clin Mol Teratol. 2010. PMID: 19637252 Free PMC article.
-
Clinical decision support to promote safe prescribing to women of reproductive age: a cluster-randomized trial.J Gen Intern Med. 2012 Jul;27(7):831-8. doi: 10.1007/s11606-012-1991-y. J Gen Intern Med. 2012. PMID: 22297687 Free PMC article. Clinical Trial.
-
Counseling about medication-induced birth defects with clinical decision support in primary care.J Womens Health (Larchmt). 2013 Oct;22(10):817-24. doi: 10.1089/jwh.2013.4262. Epub 2013 Aug 9. J Womens Health (Larchmt). 2013. PMID: 23930947 Free PMC article.
-
An update on maternal medication-related embryopathies.Prenat Diagn. 2020 Aug;40(9):1168-1177. doi: 10.1002/pd.5764. Epub 2020 Jul 28. Prenat Diagn. 2020. PMID: 32524623 Review.
-
Risk management of teratogenic medicines: A systematic review.Birth Defects Res. 2020 Dec;112(20):1755-1786. doi: 10.1002/bdr2.1799. Epub 2020 Sep 11. Birth Defects Res. 2020. PMID: 32918401 Review.
Cited by
-
Selective serotonin reuptake inhibitors (SSRIs) in women of reproductive age: a systematic review of local formularies.BJGP Open. 2024 Jul 29;8(2):BJGPO.2023.0255. doi: 10.3399/BJGPO.2023.0255. Print 2024 Jul. BJGP Open. 2024. PMID: 38272494 Free PMC article.
-
Pediatric hematology providers' contraceptive practices for female adolescents and young adults with sickle cell disease: A national survey.Pediatr Blood Cancer. 2022 Oct;69(10):e29877. doi: 10.1002/pbc.29877. Epub 2022 Jul 20. Pediatr Blood Cancer. 2022. PMID: 35856776 Free PMC article.
-
Special Considerations for Women of Reproductive Age on Anticoagulation.J Gen Intern Med. 2022 Aug;37(11):2803-2810. doi: 10.1007/s11606-022-07528-y. Epub 2022 May 31. J Gen Intern Med. 2022. PMID: 35641728 Free PMC article. Review.
-
Development and Pilot Testing of a Patient-Centered Web-Based Reproductive Decision Support Tool for Primary Care.J Gen Intern Med. 2021 Oct;36(10):2989-2999. doi: 10.1007/s11606-020-06506-6. Epub 2021 Feb 4. J Gen Intern Med. 2021. PMID: 33538956 Free PMC article.
-
"I know my body better than you:" patient focus groups to inform a decision aid on oral corticosteroid use during pregnancy.Pharmacoepidemiol Drug Saf. 2021 Apr;30(4):451-461. doi: 10.1002/pds.5183. Epub 2020 Dec 22. Pharmacoepidemiol Drug Saf. 2021. PMID: 33314542 Free PMC article.
References
-
- Andrade SE, Gurwitz JH, Davis RL, et al. Prescription drug use in pregnancy. Am J Obstet Gynecol. 2004;191:398–407. - PubMed
-
- Andrade SE, Raebel MA, Morse AN, et al. Use of prescription medications with a potential for fetal harm among pregnant women. Pharmacoepidemiol Drug Saf. 2006;15:546–54. - PubMed
-
- Andrade SE, Raebel MA, Brown J, et al. Outpatient use of cardiovascular drugs during pregnancy. Pharmacoepidemiol Drug Saf. 2008;17:240–7. - PubMed
-
- Briggs GG, Freeman RK, Yaffe SJ. A Reference Guide to Fetal and Neonatal Risk. 8. Philadelphia: Lippincott, Williams & Wilkins; 2008. Drugs in Pregnancy and Lactation.
-
- Brotherton SE, Rockey PH, Etzel SI. US graduate medical education, 2004–2005: trends in primary care specialties. Jama. 2005;294:1075–82. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
